首页> 外文期刊>Bone marrow transplantation >Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
【24h】

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.

机译:使用基于氟达拉滨的低强度调理方案进行异基因外周血干细胞移植治疗恶性淋巴瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT. We now present our experience with 23 heavily treated high risk ML patients who underwent matched alloSCT following the same low intensity conditioning. The patients (20 male, three female) were aged 13-63 years. Nineteen had NHL and four HD (resistant disease 12, partial remission 11). Five were post ABMT. Twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. Engraftment was fast. There was no rejection or non-engraftment. Organ toxicity was moderate with no liver or renal toxicity >grade II. Four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died - four of grade III-IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15-37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000).
机译:大剂量治疗和自体骨髓移植(ABMT)治疗恶性淋巴瘤(ML)后,复发是一种严重的并发症。同种异体移植(alloSCT)是一种治疗选择。但是,它与移植相关器官毒性和死亡率的高发生率有关。我们最近报道了在alloSCT之前使用基于氟达拉滨的调理方法,并减少了化学毒性药物的用量,从而实现了快速植入和与移植相关的毒性最小化。现在,我们介​​绍了23名经过相同低强度调理后接受了匹配的alloSCT的重度治疗的高危ML患者的经验。患者(男20例,女3例)年龄13-63岁。 19例有NHL和4例HD(耐药病12,部分缓解11)。 ABMT之后有5个。 22位患者具有完全匹配的兄弟姐妹供体,一个患者完全匹配的无关亲戚供体。嫁接很快。没有排斥或非植入。器官毒性中等,无肝或肾毒性> II级。四名患者发展为II级移植物抗宿主病(GVHD)。 7例患者死亡-4例III-IV级GVHD和严重感染,2例细菌性败血症,1例肺衰竭。 10个病人在22.5(15-37)个月后还活着。 37个月的生存率和无病生存率均为40%。复发的可能性是26%。这些令人鼓舞的结果表明,对高危患者进行基于氟达拉滨的低强度调节后的alloSCT值得进一步评估。骨髓移植(2000年)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号